We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen’s Next-Generation Heart Drug Enters Phase III with Positive Results
Amgen’s Next-Generation Heart Drug Enters Phase III with Positive Results
Amgen’s first long-term trial for its next-generation heart drug evolocumab has shown positive results, heating up the race to develop the emerging class of drugs known as PCSK9 inhibitors.